TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28784670

Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28785295

Group type: EXPERIMENTAL
Intervention: ~60 g/d almonds (ALM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: NCEP step II diet (CON)
Number of subjects: 33
Study: 28785768

Group type: EXPERIMENTAL
Intervention: Phenotype A (n=466)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Phenotype B (n=164)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Phenotype C (n=252)
Number of subjects: 882

Group type: COMPARATOR
Intervention: Phenotype B vs A
Number of subjects: 882

Group type: COMPARATOR
Intervention: Phenotype C vs A
Number of subjects: 882
Study: 28785771

Group type: EXPERIMENTAL
Intervention: Nurse practitioners (NPs)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Primary care physicians (PCPs)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Specialist physicians
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 600
Study: 28786339

Group type: EXPERIMENTAL
Intervention: Palliative care for prisoners (n=50)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Temporary or permanent compassionate release eligibility (n=44)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Request for suspension or reduction in sentence on medical grounds (n=48)
Number of subjects: 50
Study: 28786987

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch therapy for 24 weeks in patients with minimal WMHs (group 1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch therapy for 24 weeks in patients with moderate WMHs (group 2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adverse events rates
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Discontinuation due to adverse events
Number of subjects: 300
Study: 28787430

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel (G/D) window therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel (G/D)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard risk (SR) patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: High risk (HR) patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patients aged ⩽18 years
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patients aged >18 years
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: mP6 regimen
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 43
Study: 28787656

Group type: EXPERIMENTAL
Intervention: Active suicidal ideation (SI)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Neuroimaging procedure
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Assessment of active SI after three days
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficients (ICCs) for SI and pessimism
Number of subjects: 269
Study: 28789693

Group type: EXPERIMENTAL
Intervention: PCOS mothers
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-PCOS controls
Number of subjects: 21
Study: 28789851

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (4th dose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (3 doses)
Number of subjects: 150
Study: 28790169

Group type: EXPERIMENTAL
Intervention: Baseline understanding of rhythm control, ablation, anticoagulation, and cardioversion
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: 6-month follow-up understanding of warfarin and direct oral anticoagulants (DOACs)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Understanding of oral anticoagulant benefits at diagnosis
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Overall understanding of AF treatment at 6 months
Number of subjects: 1004
Study: 28791297

Group type: EXPERIMENTAL
Intervention: 4 g omega-3 (OMACOR) daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 228
Study: 28791628

Group type: EXPERIMENTAL
Intervention: Surgical approach using mitomycin C (MMC) at a dose of 25 mg/m
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Percutaneous approach using mitomycin C (MMC) at a dose of 25 mg/m
Number of subjects: 18
Study: 28791698

Group type: EXPERIMENTAL
Intervention: Fenoterol (180 µg) administered to OCT1-deficient individuals (n=5)
Number of subjects: 39
Study: 28791776

Group type: EXPERIMENTAL
Intervention: WHO/FAO/UNU W
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Harris and Benedict, Müller and Lazzer equations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: De Luis equation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ireton-Jones equation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WHO/FAO/UNU W and WHO/FAO/UNU WH, Müller and Lazzer equations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WHO/FAO/UNU W and WHO/FAO/UNU WH formulas
Number of subjects: 30
Study: 28792613

Group type: EXPERIMENTAL
Intervention: Different pressure regimes applied to healthy subjects and hospitalized patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler laser measurements of vascular flow, tissue oxygenation, and local temperature.
Number of subjects: 0
Study: 28792880

Group type: EXPERIMENTAL
Intervention: EBV DNA in plasma samples
Number of subjects: 20174
Study: 28793098

Group type: EXPERIMENTAL
Intervention: Telephone support (G1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mailing educational material (G2)
Number of subjects: 63
Study: 28793152

Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis stimulation for character identification
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis stimulation for static image localization
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis stimulation for dynamic image localization
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Eye tracking assessment
Number of subjects: 3
Study: 28793317

Group type: EXPERIMENTAL
Intervention: PA/MD model
Number of subjects: 2307

Group type: COMPARATOR
Intervention: MD model
Number of subjects: 2307
Study: 28793871

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 44
Study: 28793881

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Ophthalmologist-dominant decision-making (ODM)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Patient-dominant decision-making (PDM)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Older patients preferring ODM
Number of subjects: 810

Group type: COMPARATOR
Intervention: Patients with lower education preferring ODM
Number of subjects: 810

Group type: COMPARATOR
Intervention: Patients with higher consultation frequency preferring ODM
Number of subjects: 810
Study: 28793888

Group type: EXPERIMENTAL
Intervention: Patients with structural leg-length discrepancy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with shorter leg in front position
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with shorter leg in rear position
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls (eyes open)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients (eyes open)
Number of subjects: 38
Study: 28793946

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for PCPs
Number of subjects: 227
Study: 28793994

Group type: EXPERIMENTAL
Intervention: Total Unsaturated Fatty Acids (UFAs)
Number of subjects: 4146

Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids (PUFAs)
Number of subjects: 4146

Group type: EXPERIMENTAL
Intervention: Cis Monounsaturated Fatty Acids (MUFAs)
Number of subjects: 4146
Study: 28794078

Group type: EXPERIMENTAL
Intervention: SB4 (50 mg weekly subcutaneous administration)
Number of subjects: 245

Group type: COMPARATOR
Intervention: ETN (50 mg weekly subcutaneous administration)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: SB4 (SB4/SB4)
Number of subjects: 245

Group type: COMPARATOR
Intervention: ETN (ETN/SB4)
Number of subjects: 245
Study: 28794136

Group type: EXPERIMENTAL
Intervention: Preoperative serum neutrophil gelatinase-associated lipocalin (sNGAL) levels in the last tertile (>220 ng/L)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Postoperative acute kidney injury (AKI) defined using the International Kidney Disease: Improving Global Outcomes classification
Number of subjects: 1371
Study: 28794139

Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillator for primary prevention of sudden cardiac arrest
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Greater volume of denervated myocardium (defect of the positron emission tomography norepinephrine analog)
Number of subjects: 204
Study: 28794175

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28794208

Group type: EXPERIMENTAL
Intervention: Increasing amounts of chicken intake (from 88 to 290 g/d) over 3 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Consumers of chicken (based on National Adult Nutrition Survey)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reported chicken intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma metabolite analysis
Number of subjects: 10
Study: 28794257

Group type: EXPERIMENTAL
Intervention: Screening for mutations using a high-coverage ataxia-specific gene panel and next-generation sequencing
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 249
Study: 28794888

Group type: EXPERIMENTAL
Intervention: Fried foods ≥5 servings/week
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Soda intake
Number of subjects: 888
Study: 28794898

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Fixed dose combination pill
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Incident hypertensive patients
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Treated hypertensive patients
Number of subjects: 1318
Study: 28795156

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted brace casting (US group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (Providence brace design system)
Number of subjects: 34
Study: 28795383

Group type: EXPERIMENTAL
Intervention: Integrated Imaginative Distention (IID) therapy, delivered as eight weekly training group sessions by a skilled psychotherapist.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Waiting list control group (C)
Number of subjects: 144
Study: 28795890

Group type: EXPERIMENTAL
Intervention: Bacterial fluorescence image-guided curettage or biopsy sampling
Number of subjects: 60
Study: 28796275

Group type: EXPERIMENTAL
Intervention: Immature platelets (IPF) measured postoperatively in the PACU
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Optimal cut off of IPF > 5.4%
Number of subjects: 732
Study: 28796410

Group type: EXPERIMENTAL
Intervention: Fibrosis 4 index (FIB-4)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: BARD
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: NAFLD fibrosis score (NFS)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: ARFI
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: NFS
Number of subjects: 315
Study: 28796812

Group type: EXPERIMENTAL
Intervention: ONCOS-102 (Ad5/3-D24-GM-CSF) administered by intracardial, intraperitoneal or subcutaneous injections
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide administered intraperitoneally twice a week
Number of subjects: 300

Group type: COMPARATOR
Intervention: NaCl solution administered to control group
Number of subjects: 300
Study: 28796864

Group type: EXPERIMENTAL
Intervention: Individualized adaptive stereotactic body radiotherapy (SBRT)
Number of subjects: 90
Study: 28797193

Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (800-1200 mg)
Number of subjects: 106
Study: 28797263

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) with sulfadoxine + amodiaquine (SP + AQ)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison district (Bafoulabe)
Number of subjects: 15
Study: 28797270

Group type: EXPERIMENTAL
Intervention: Teen Marijuana Check-Up (TMCU) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: As-needed technical assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gold-standard technical assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist/control group
Number of subjects: 0
Study: 28797293

Group type: EXPERIMENTAL
Intervention: CDS intervention
Number of subjects: 18
Study: 28797351

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 985
Study: 28797353

Group type: EXPERIMENTAL
Intervention: TAVR with next-generation self-expanding transcatheter heart valve (THV) system
Number of subjects: 1038
Study: 28797458

Group type: EXPERIMENTAL
Intervention: APF-C (nab-paclitaxel/cisplatin/5-FU + cetuximab)
Number of subjects: 60

Group type: COMPARATOR
Intervention: APF (nab-paclitaxel/cisplatin/5-FU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: APF-C
Number of subjects: 60

Group type: COMPARATOR
Intervention: APF
Number of subjects: 60
Study: 28797782

Group type: EXPERIMENTAL
Intervention: Systemic therapy for cGVHD
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lower NIH global severity scores
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lower lung scores
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Less extensive deep sclerosis (<37% body surface area)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lower patient- and clinician-reported 0 to 10 severity NIH scores
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Noncyclosporine prophylaxis regimens
Number of subjects: 227
Study: 28797911

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-free biliary cannulation, sphincterotomy, and cholangioscopy for stone extraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 40
Study: 28798042

Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR)
Number of subjects: 181
Study: 28798091

Group type: EXPERIMENTAL
Intervention: Quadriceps strength training, duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional assessments related to quadriceps strength, details not available.
Number of subjects: 0
Study: 28798090

Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Number of subjects: 0
Study: 28798986

Group type: EXPERIMENTAL
Intervention: Tasquinimod (0.5 mg/day for at least 2 weeks, increased to 1 mg/day)
Number of subjects: 167
Study: 28799258

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 590

Group type: COMPARATOR
Intervention: Persistent H. pylori infection
Number of subjects: 590

Group type: COMPARATOR
Intervention: Serum ratio of PGI:PGII of three or less at the time of endoscopic submucosal dissection
Number of subjects: 590

Group type: COMPARATOR
Intervention: Persistent decrease in mean serum ratio of PGI:PGII to 3 or less
Number of subjects: 590
Study: 28800492

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone/prednisolone (AAP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 82
Study: 28800628

Group type: EXPERIMENTAL
Intervention: Sotalol 80mg oral dose
Number of subjects: 990
Study: 28801186

Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide (12 4-week cycles of 150-200 mg/m²) with radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy) alone
Number of subjects: 745
Study: 28801338

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (not treated with rituximab)
Number of subjects: 77
Study: 28801404

Group type: COMPARATOR
Intervention: Preoperative physical activity (active)
Number of subjects: 5733
Study: 28801407

Group type: EXPERIMENTAL
Intervention: Dyspnoeic individuals
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-dyspnoeic individuals
Number of subjects: 240
Study: 28801417

Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter (ONSD) sonography
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT scan, MRI, ICP monitor, lumbar puncture (LP)
Number of subjects: 0
Study: 28801442

Group type: EXPERIMENTAL
Intervention: Community-based intervention for environmental enteric dysfunction (EED)
Number of subjects: 3
Study: 28801477

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Impaired renal function (eCCl <60 mL/min)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Both T2DM and eCCl <60 mL/min
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Cognitive decline (mild cognitive impairment or dementia)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: T2DM and lower eCCl
Number of subjects: 507
Study: 28801537

Group type: EXPERIMENTAL
Intervention: AMPLATZER Septal Occluder
Number of subjects: 1000
Study: 28801539

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2010
Study: 28802168

Group type: EXPERIMENTAL
Intervention: HBV vaccine (30µg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no HBV vaccine)
Number of subjects: 220
Study: 28802255

Group type: EXPERIMENTAL
Intervention: Sym015, an antibody mixture composed of two humanized IgG
Number of subjects: 0
Study: 28802755

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination in pneuCAP patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination in otherCAP patients
Number of subjects: 60
Study: 28802811

Group type: EXPERIMENTAL
Intervention: Pressure threshold respiratory training (RT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Untrained control subjects
Number of subjects: 44
Study: 28803122

Group type: EXPERIMENTAL
Intervention: FDC tablet of rosuvastatin 20 mg/ezetimibe 10 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Co-administration of rosuvastatin 20 mg and ezetimibe 10 mg
Number of subjects: 64
Study: 28803351

Group type: EXPERIMENTAL
Intervention: Weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28-day cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ixazomib with lenalidomide and dexamethasone (IRd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ixazomib exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixazomib systemic exposure
Number of subjects: 0
Study: 28803675

Group type: EXPERIMENTAL
Intervention: Fitness center intervention (structured thrice weekly aerobic and resistance exercise program, supervised for the first 6 months)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fitness center intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Home based physical activity group
Number of subjects: 154
Study: 28804454

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy using a novel rehabilitation device
Number of subjects: 4
Study: 28804864

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 416
Study: 28805662

Group type: EXPERIMENTAL
Intervention: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts) infused at doses of 0.2 × 10^8 to 2 × 10^8 CD30.CAR-Ts/m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts)
Number of subjects: 9
Study: 28806216

Group type: EXPERIMENTAL
Intervention: Psoas blocks
Number of subjects: 22434

Group type: COMPARATOR
Intervention: Femoral blocks
Number of subjects: 22434
Study: 28806373

Group type: EXPERIMENTAL
Intervention: H-PACT
Number of subjects: 3981

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3981

Group type: COMPARATOR
Intervention: Nonenrolled
Number of subjects: 3981
Study: 28806894

Group type: EXPERIMENTAL
Intervention: Mental Health Courts (MHCs)
Number of subjects: 16129

Group type: COMPARATOR
Intervention: Traditional criminal processing
Number of subjects: 16129
Study: 28806957

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Molecular markers analysis (k13, pfarps10, pffd, pfmdr2)
Number of subjects: 1160
Study: 28806961

Group type: EXPERIMENTAL
Intervention: Chloroquine resistance (pfcrt K76T mutation)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: pfmdr1 N86Y mutation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: k13 propeller region mutations
Number of subjects: 130
Study: 28807017

Group type: EXPERIMENTAL
Intervention: Orally applied metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 0
Study: 28807118

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma combined with hyaluronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28807382

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1200
Study: 28807448

Group type: EXPERIMENTAL
Intervention: 2-D shear wave elastography (2-D-SWE)
Number of subjects: 121
Study: 28807914

Group type: EXPERIMENTAL
Intervention: Ceftriaxone exposure
Number of subjects: 122
Study: 28808182

Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28808360

Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU anti-factor Xa, subcutaneous injection once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg, subcutaneous injection once daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 100
Study: 28808443

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor) for 1 week
Number of subjects: 27
Study: 28808480

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy with modified EPIC regimen (etoposide, prednisolone, ifosfamide, cisplatin), median 3 cycles (range 1-6)
Number of subjects: 21